reports
- ABGSC Financials Research
- Fredrik Flørnes Støle
- Simon Brun
Millicom (Tigo) notice of fourth quarter 2025 results and video confer...
Millicom (Tigo) notice of fourth quarter 2025 results and video conference Millicom (Tigo) notice of fourth quarter 2025 results and video conference Luxembourg, February 13, 2026 – Millicom (NASDAQ: TIGO) expects to announce its fourth quarter 2025 results on February 26, 2026, via a press release. Millicom is planning to host a video conference for the global financial community on February 26, 2026, at 08:00 (New York) / 14:00 (Luxembourg) / 13:00 (London). Registration for the interactive event is required at the following . After registering, you will receive a confirmation e...
- ABGSC Financials Research
- Fredrik Flørnes Støle
- Simon Brun
- ABGSC Services Research
- Julia Sundvall
- Simon Jönsson
Swedish Orphan Biovitrum AB: 1 director
A director at Swedish Orphan Biovitrum AB maiden bought 1,900 shares at 405.333SEK and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the l...
- ABGSC Services Research
- Julia Sundvall
- Simon Jönsson
Millicom (Tigo) acquires Telefonica operations in Chile jointly with N...
Millicom (Tigo) acquires Telefonica operations in Chile jointly with NJJ, structured to capture strategic value while protecting its balance sheet Millicom (Tigo) acquires Telefonica operations in Chile jointly with NJJ, structured to capture strategic value while protecting its balance sheet Key Highlights: Joint acquisition through a 49%/51% partnership between Millicom International Cellular S.A. (“Millicom”) and NJJ. Transaction structured with an initial closing payment of $50 million and additional earn-out consideration up to $150 million based on structural value creation and n...
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
- Morten Larsen
Millicom (Tigo) Successfully Concludes Tender Offer for Telefónica’s C...
Millicom (Tigo) Successfully Concludes Tender Offer for Telefónica’s Controlling Stake in Colombia Telecomunicaciones S.A. E.S.P. (Coltel) Millicom (Tigo) Successfully Concludes Tender Offer for Telefónica’s Controlling Stake in Colombia Telecomunicaciones S.A. E.S.P. (Coltel) Luxembourg, February 5, 2026 – Millicom International Cellular S.A. (“Millicom”) today announced it has successfully concluded a tender offer for the acquisition of Telefónica’s controlling 67.5% equity stake in Colombia Telecomunicaciones S.A. E.S.P. (“Coltel”). The closing of the acquisition is expected to take p...
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
- Morten Larsen
Millicom (Tigo) announces successful bid for EPM’s Stake in UNE
Millicom (Tigo) announces successful bid for EPM’s Stake in UNE Millicom (Tigo) announces successful bid for EPM’s Stake in UNE Luxembourg, January 27,2026 — Millicom International Cellular S.A. ("Millicom") today announced that it has been awarded 100% of EPM’s remaining shares in UNE EPM Telecommunicaciones S.A. (“UNE” or “Tigo Colombia”), following a winning bid in the public auction conducted by Empresas Públicas de Medellín E.S.P. ("EPM"). Millicom’s bid was COP 418,741 per share, representing a total consideration of approximately COP 2.1 trillion, (approximately USD 571 million). T...
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
- Morten Larsen
- Chris Hoare
LatAm Telcos Outlook 2026 – Consolidation moves to broadband + Millic...
Fundamentals continue to look pretty good to us in Latin America, with market repair continuing across wireless markets, and further consolidation likely. Despite a strong 2025, valuations still look compelling across the region in our view too. Top picks: Liberty Latin America, Vivo, AMX and Megacable. We also upgrade our Millicom pt to $70.
- ABGSC Healthcare Research
- Georg Tigalonov-Bjerke
- Morten Larsen
Comunicaciones Celulares S.A. Resolves DOJ Investigation Related to Hi...
Comunicaciones Celulares S.A. Resolves DOJ Investigation Related to Historical Conduct Comunicaciones Celulares S.A. Resolves DOJ Investigation Related to Historical Conduct Luxembourg, November 10, 2025 – Millicom International Cellular S.A. (“Millicom”) today announced that its subsidiary, Comunicaciones Celulares S.A. (“Comcel”), has reached an agreement with the U.S. Department of Justice (“DOJ”) to resolve an investigation concerning historical improper payments made to Guatemalan government officials. At the time of the conduct, Comcel operated as a joint venture over which Millico...
- ABGSC Financials Research
- Fredrik Flørnes Støle
- Simon Brun
Millicom (Tigo) Q3 2025 Earnings Release
Millicom (Tigo) Q3 2025 Earnings Release Millicom (Tigo) Q3 2025 Earnings Release Luxembourg, November 6, 2025 – is pleased to announce its third quarter 2025 results. Please find below links to the Q3 2025 Earnings Release and IAS 34 Interim Condensed Consolidated Financial Statements. Q3 2025 Highlights* Revenue $1.42 billion Operating profit $390 million, and record Adjusted EBITDA $695 million Net profit attributable to company owners $195 million, including approximately $138 million net profit from the closure of infrastructure transactions Equity free cash flow $243 million ...
- ABGSC Financials Research
- Fredrik Flørnes Støle
- Simon Brun
Data presented at ACR Convergence 2025 highlight Sobi’s commitment to ...
Data presented at ACR Convergence 2025 highlight Sobi’s commitment to advancing care across rare and underserved inflammatory conditions NASP data highlight reduction in disease burden among people living with uncontrolled gout Gamifant (emapalumab) data showed response rates in patients with MAS in Still’s disease across MAS subtypes, including in those with recurrent disease Discussion of the first ever international, randomized, multicentre, double-blind, placebo-controlled phase 2 dose finding trial of Vonjo® (pacritinib) in adult patients with VEXAS syndrome WALTHAM, Mass., Oct. 25...
- ABGSC Services Research
- Julia Sundvall
- Simon Jönsson
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.